Search
Oxyquinoline
go.drugbank.com/drugs/DB11145ApprovedInvestigationalVet approvedIt is used as a stabilizer for hydrogen peroxide, where it is sometimes added in cosmetic products. … Oxyquinoline is a heterocyclic phenol and derivative of quinoline with antiseptic, disinfectant, and pesticide properties.
Categories: Antiinfectives and Antiseptics for Local Oral TreatmentAminoglutethimide
go.drugbank.com/drugs/DB00357ApprovedWithdrawnIt was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454) … An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens.
Besilesomab
go.drugbank.com/drugs/DB13979ApprovedBesilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis … Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the
Debrisoquine
go.drugbank.com/drugs/DB04840ApprovedIt is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. … They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalgene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. … Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow.
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A3 Substrates with a Narrow Therapeutic IndexAlglucerase
go.drugbank.com/drugs/DB00088ApprovedWithdrawnHuman Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD.
Mesalazine
go.drugbank.com/drugs/DB00244ApprovedInvestigationalAlthough demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent
Inebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigationalInappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis … [A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19.
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnSomatostatin, also known as growth hormone-inhibiting hormone, is a naturally-occurring peptide hormone of 14 or 28 amino acid residues [T28] that regulates the endocrine system. … [DB00104] is a long-acting analogue of somatostatin that inhibits the release of a number of hormones, and is clinically used to relieve symptoms of uncommon gastroenteropancreatic endocrine tumours, as
Products: STILAMIN 3000 FOR INJECTION 3 mg/ampouleSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalSunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. … For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic IndexProducts: Sunitinib 1A Pharma 12,5 mg - Hartkapseln, Sunitinib 1A Pharma 25 mg - Hartkapseln